collaborate.

innovate.

accelerate.
Over the past year, Critical Path Institute (C-Path) has made continuous strides to increase the reach of our organization as a trusted leader in orchestrating successful collaborations across many sectors where disease burden is still high due to the need for new methods and tools which have the potential to accelerate the development of safe, effective medical products. As an example, we established an entity in the United Kingdom, Critical Path Global, Ltd., and have received Small/Medium Enterprise designation with the European Medicines Agency (EMA). This allows us to submit our work to the European Medicines Agency at a 90% discount, making it affordable to provide the same regulatory advancements in Europe that we are progressing within the United States.

In our seventh full year of operation, C-Path is now leading seven very active scientific consortia across multiple disease areas and attaining recognition as a global leader in leading scientific consortia to highly meaningful deliverables. In addition to the Alzheimer’s Disease Standard we finalized in 2011, this past year we completed the work for a new Tuberculosis Disease Data Standard and a new Parkinson’s Disease Data Standard. These new standards position C-Path well to develop new drug development tools in these disease areas.

In my first few months as President and CEO of C-Path, I am energized by the talented and dedicated staff at C-Path and their track record for accomplishment. Having recently returned from C-Path’s first-ever public meeting in Europe, which was jointly sponsored with the Innovative Medicines Initiative, I am even more inspired to lead C-Path into the future as we succeed in achieving global progress towards advancing regulatory science. This meeting enabled C-Path to gain recognition with a broader audience of scientists, government policy makers, civil society organizations, and media.

As an independent non-profit organization, the financial and in-kind support we receive allows C-Path to continue to lead global efforts to develop new methods and tools to accelerate the process of getting new medicines to patients who need them. We encourage our supporters and collaborators to take pride in what you have helped to create at C-Path, and to join with us in our continued journey.

Sincerely,

Martha A. Brumfield, PhD
President and CEO
C-PATH CONSORTIA

Predictive Safety Testing Consortium (PSTC)

PSTC brings together pharmaceutical companies to share and validate innovative safety testing methods under advisement of the FDA, EMA, and PMDA.

Coalition Against Major Diseases (CAMD)

CAMD was created to develop innovative approaches and processes to accelerate drug development tools for the treatment of chronic neurodegenerative diseases.

Patient-Reported Outcome (PRO) Consortium

PRO Consortium was created to develop and qualify PRO Instruments for use as primary or key secondary endpoints in clinical trials.

Electronic Patient-Reported Outcome (ePRO) Consortium

The ePRO Consortium was created to facilitate the implementation of patient-reported outcome instruments onto electronic platforms such as smartphones, tablet computers, the web, or interactive voice response systems.

Polycystic Kidney Disease (PKD) Consortium

The PKD Outcomes Consortium is a collaboration between the PKD Foundation, the FDA, C-Path, and clinician scientists to address the significant unmet need for effective drug therapies for Polycystic Kidney Disease.

Critical Path to TB Drug Regimens (CPTR)

The CPTR initiative is a public-private partnership led by the Critical Path Institute, the Bill & Melinda Gates Foundation, and the Global TB Alliance focused on enabling the accelerated development of new treatment regimens for TB. Related work being conducted includes advancing novel biomarkers and data standards, developing a TB disease progression models and clinical trial simulation tools as well as enhancing global regulatory pathways for new regimens.

Multiple Sclerosis Outcome Assessments Consortium (MSOAC)

The primary purpose of the MSOAC is to achieve qualification at the FDA and EMA of a clinician-reported outcome (ClinRO) instrument as a primary or co-primary endpoint in clinical trials of MS therapies.
This fiscal year was one of transition for Critical Path Institute. On February 1, 2012, Carolyn Compton, M.D., Ph.D., took the reins as the new President and CEO as the founder, Dr. Ray Woosley, moved on to be the President and Chairman of the Board of AZCERT. In March of 2012, Steven Broadbent became the new Chief Operating Officer, taking over for Rick Myers, who was appointed as the chairman of the Arizona Board of Regents. Shortly after that, the leadership at C-Path identified new strategies that focused on expanding our core competencies into new therapeutic areas, diversifying our funding sources, and enhancing our methods of communicating with our stakeholders. These efforts are underway and are bearing fruit.

In February of 2012, the C-Path Board of Directors approved the use of fees collected from our consortia members specifically for C-Path staff. This was done after careful consultation with both the FDA and our industry partners to ensure it would not damage our reputation as a neutral third party, which is critical to our success. Together with the grants from the government and private foundations, these fees have enabled C-Path to continue to be financially strong in a challenging economy.

C-Path is continuing its evolution from a startup organization to a small, stable and mature organization. The $12 million in initial funding from the local community and the $14 million from Science Foundation Arizona have enabled C-Path to become firmly established and recognized in the nation and around the world as an organization with a track record of successful accomplishments. Several organizations have approached us with a desire to partner or fund efforts that are important to them and that align with our mission and core competencies. C-Path is now receiving grants from the U. S. Food and Drug Administration, the Bill & Melinda Gates Foundation, the Polycystic Kidney Disease Foundation, and the National Multiple Sclerosis Society for specified projects. As part of an overall effort to become more efficient, the decision was made to reduce the non-scientific staff. With the potential projects in the pipeline, we anticipate adding scientific staff next year.

Philanthropy remains an important source of funding for C-Path. We’re grateful to those who continue to support us because they share our vision of accelerating the development of new therapies by reducing the time, cost, and risk of bringing these medicines to those who need them.

The steadfast support of our community, the passion and dedication of our scientists and staff, and the trust of our stakeholders continue to enable C-Path to fulfill its mission.
Seven consortia, 1,000+ scientists, and 41 member companies

Seven safety biomarkers qualified by the FDA, EMA, and PMDA (the Japanese counterpart) and in use by industry

First imaging biomarker qualification by the EMA to enrich Alzheimer’s disease clinical trials

Data standards published for Alzheimer’s disease
developed with Clinical Data Interchange Standards Consortium

Data standards published for Tuberculosis
developed with Clinical Data Interchange Standards Consortium

Data standards published for Parkinson’s disease
developed with Clinical Data Interchange Standards Consortium

Data standards published for Polycystic Kidney disease
developed with Clinical Data Interchange Standards Consortium

Database of aggregated Alzheimer’s Disease clinical trial data
(6,500 patients and 24 clinical trials) - publicly available to qualified researchers

First Alzheimer’s disease progression model and simulation platform in review by the FDA

Launched the Coalition For Accelerating Standards and Therapies. (CFAST) in partnership with CDISC

Established a European subsidiary, Critical Path Global, Ltd.

Won Arizona Bio-industry (AZBIO) “Fast Lane Award” for outstanding achievement
We want to thank the U.S. Food and Drug Administration and Science Foundation Arizona for their significant funding of our work.
MISSION
To improve health and save lives by accelerating the development of safe, effective medicines.

VISION
To be the global leader in creating collaborations that advance scientific innovations to improve human health.